Katja K.
- Country
- Germany
- Department
- Brustzentrum
Research Overview
- Comparison of Adjuvant Elacestrant with Standard Endocrine Therapy in High-Risk ER+/HER2- Early Breast Cancer
- Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab versus Chemotherapy in Clinical Stage II-III Triple-Negative Early Breast Cancer
- Phase 2 Open‑Label Study of LY3484356 (imlunestrant) versus Tamoxifen or LY3484356 + Goserelin in Premenopausal ER‑Positive HER2‑Negative Early Breast Cancer
Data & Insights
Has run more than one trial at 125 of 314 partner sites.
Specializations
Breast Cancer Research
This investigator specializes in advanced therapeutic approaches for estrogen receptor-positive breast cancer, with particular focus on treatment strategies for patients whose disease has progressed following initial therapies.
- Advanced Breast Cancer Management
- Hormone Receptor-Positive Disease
- Treatment-Resistant Cases
The research encompasses innovative therapeutic combinations for HER2-negative breast cancer patients.
Molecular Oncology
The investigator's work centers on understanding and treating ESR1-mutated breast cancer, representing expertise in precision medicine approaches to oncology.
- Mutation-Specific Treatments
- Endocrine Therapy Resistance
- Targeted Therapeutic Strategies
Special attention is given to developing treatments for patients with specific genetic alterations affecting treatment response.
Treatment Innovation
The investigator explores novel therapeutic combinations targeting advanced breast cancer, particularly focusing on overcoming resistance to standard treatments.
- Combination Therapy Approaches
- Drug Resistance Management
- Progressive Disease Treatment
Research interests include developing strategies for patients who have progressed on CDK4/6 inhibitor therapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.